Treatment of pregnancy complications

Barbara Acaia, Federica Rossi, Cecilia Beatrice Chighizola

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pregnancy morbidity and vascular thrombosis provide the clinical manifestations of the antiphospholipid syndrome (APS), a chronic autoimmune condition serologically characterized by the positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of the treatment of obstetric APS. However, the debate is still open: controversies involve the management of rare aPL-mediated obstetric complications, the treatment of vascular manifestations, and the treatment of refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. In addition, no treatment trial has ever investigated the optimal treatment of aPL women stratifying upon the different risk profile (aPL profile, associated autoimmune disease, previous obstetrical history). The recommended therapeutic managements of different aPL-related obstetrical clinical manifestations are hereby presented, with a critical appraisal of the evidence supporting each approach.

Original languageEnglish
Title of host publicationAntiphospholipid Antibody Syndrome: From Bench to Bedside
PublisherSpringer International Publishing
Pages193-206
Number of pages14
ISBN (Print)9783319110448, 9783319110431
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Pregnancy Complications
Antiphospholipid Antibodies
Antiphospholipid Syndrome
Obstetrics
Blood Vessels
Therapeutics
Platelet Aggregation Inhibitors
Anticoagulants
Patient Selection
Autoimmune Diseases
Thrombosis
History
Morbidity
Pregnancy

Keywords

  • Antiphospholipid syndrome
  • Pregnancy morbidity
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Acaia, B., Rossi, F., & Chighizola, C. B. (2015). Treatment of pregnancy complications. In Antiphospholipid Antibody Syndrome: From Bench to Bedside (pp. 193-206). Springer International Publishing. https://doi.org/10.1007/978-3-319-11044-8_16

Treatment of pregnancy complications. / Acaia, Barbara; Rossi, Federica; Chighizola, Cecilia Beatrice.

Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing, 2015. p. 193-206.

Research output: Chapter in Book/Report/Conference proceedingChapter

Acaia, B, Rossi, F & Chighizola, CB 2015, Treatment of pregnancy complications. in Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing, pp. 193-206. https://doi.org/10.1007/978-3-319-11044-8_16
Acaia B, Rossi F, Chighizola CB. Treatment of pregnancy complications. In Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing. 2015. p. 193-206 https://doi.org/10.1007/978-3-319-11044-8_16
Acaia, Barbara ; Rossi, Federica ; Chighizola, Cecilia Beatrice. / Treatment of pregnancy complications. Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing, 2015. pp. 193-206
@inbook{7dd028b3bdca4a4db5a383d160a2f21e,
title = "Treatment of pregnancy complications",
abstract = "Pregnancy morbidity and vascular thrombosis provide the clinical manifestations of the antiphospholipid syndrome (APS), a chronic autoimmune condition serologically characterized by the positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of the treatment of obstetric APS. However, the debate is still open: controversies involve the management of rare aPL-mediated obstetric complications, the treatment of vascular manifestations, and the treatment of refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. In addition, no treatment trial has ever investigated the optimal treatment of aPL women stratifying upon the different risk profile (aPL profile, associated autoimmune disease, previous obstetrical history). The recommended therapeutic managements of different aPL-related obstetrical clinical manifestations are hereby presented, with a critical appraisal of the evidence supporting each approach.",
keywords = "Antiphospholipid syndrome, Pregnancy morbidity, Treatment",
author = "Barbara Acaia and Federica Rossi and Chighizola, {Cecilia Beatrice}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-11044-8_16",
language = "English",
isbn = "9783319110448",
pages = "193--206",
booktitle = "Antiphospholipid Antibody Syndrome: From Bench to Bedside",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Treatment of pregnancy complications

AU - Acaia, Barbara

AU - Rossi, Federica

AU - Chighizola, Cecilia Beatrice

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pregnancy morbidity and vascular thrombosis provide the clinical manifestations of the antiphospholipid syndrome (APS), a chronic autoimmune condition serologically characterized by the positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of the treatment of obstetric APS. However, the debate is still open: controversies involve the management of rare aPL-mediated obstetric complications, the treatment of vascular manifestations, and the treatment of refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. In addition, no treatment trial has ever investigated the optimal treatment of aPL women stratifying upon the different risk profile (aPL profile, associated autoimmune disease, previous obstetrical history). The recommended therapeutic managements of different aPL-related obstetrical clinical manifestations are hereby presented, with a critical appraisal of the evidence supporting each approach.

AB - Pregnancy morbidity and vascular thrombosis provide the clinical manifestations of the antiphospholipid syndrome (APS), a chronic autoimmune condition serologically characterized by the positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of the treatment of obstetric APS. However, the debate is still open: controversies involve the management of rare aPL-mediated obstetric complications, the treatment of vascular manifestations, and the treatment of refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. In addition, no treatment trial has ever investigated the optimal treatment of aPL women stratifying upon the different risk profile (aPL profile, associated autoimmune disease, previous obstetrical history). The recommended therapeutic managements of different aPL-related obstetrical clinical manifestations are hereby presented, with a critical appraisal of the evidence supporting each approach.

KW - Antiphospholipid syndrome

KW - Pregnancy morbidity

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84944579800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944579800&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-11044-8_16

DO - 10.1007/978-3-319-11044-8_16

M3 - Chapter

AN - SCOPUS:84944579800

SN - 9783319110448

SN - 9783319110431

SP - 193

EP - 206

BT - Antiphospholipid Antibody Syndrome: From Bench to Bedside

PB - Springer International Publishing

ER -